Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals develops, manufactures, markets and distributes medicines for retail, hospital, institutional and government customers. It has three segments: Affordable Medicines, Specialty and AvKARE. Affordable Medicines includes retail generics, injectables and biosimilars, with more than 280 product families in the United States. Specialty develops and sells branded medicines focused primarily on central nervous system and endocrine disorders, including CREXONT®, RYTARY®, UNITHROID® and Brekiya®. AvKARE distributes pharmaceuticals and other products to U.S. government, retail and institutional markets, and repackages medicines and vitamins under the AvKARE and AvPAK names. Amneal sells products through wholesalers, distributors, pharmacies, hospitals and institutions, and promotes branded products directly to physicians and healthcare providers. It also supplies medicines to government agencies, including the U.S. Department of Defense and the U.S. Department of Veterans Affairs. The company operates principally in the United States, India and Ireland, with manufacturing sites and co-located research and development centers in those countries.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AMRX in the last 30 days.
See all $AMRX insider activity →Amneal Pharmaceuticals reported Q3 2026 revenue of $862.68M, up 10% YoY, but net income turned to a loss of $21.7M. Growth in Affordable Medicines and Specialty segments was offset by lower AvKARE sales and acquisition costs. EPS was ($0.06).
JP Morgan kept its Overweight rating on Amneal Pharmaceuticals and increased its price target to $25 from $24, suggesting a 23.7% upside from the Nov 3 close of $20.21, according to the bank.
Amneal Pharmaceuticals, Inc. (AMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS – Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance – BRIDGE
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AMRX (Amneal Pharmaceuticals, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent AMRX coverage spans financial news, earnings and regulation.
The loss and negative EPS suggest downward pressure on the stock.
Analyst upgrade suggests upside potential.
Guidance raise suggests stronger future cash flow and earnings.
Quarterly loss widened despite revenue growth; guidance raised but loss outlook remains negative.
Rising demand and capacity expansion could lift Amneal's earnings outlook.
AlphAI scores every news story that mentions AMRX with an AI model for sentiment and relevance, and aggregates insider trades from Amneal Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Amneal Pharmaceuticals reported Q3 2026 revenue of $862.68M, up 10% YoY, but net income turned to a loss of $21.7M. Growth in Affordable Medicines and Specialty segments was offset by lower AvKARE sales and acquisition costs. EPS was ($0.06).
JP Morgan kept its Overweight rating on Amneal Pharmaceuticals and increased its price target to $25 from $24, suggesting a 23.7% upside from the Nov 3 close of $20.21, according to the bank.
Amneal Pharmaceuticals, Inc. (AMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS – Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance – BRIDGE
Amneal Pharma (AMRX) reported a wider Q3 loss of $21.69M, up from $2.37M YoY, despite 10% revenue growth to $862.68M. Adjusted EPS rose 53% to $0.26. The company raised FY26 revenue guidance to $3.15B-$3.25B and adjusted EBITDA to $800M-$815M. AMRX stock is down 1.17% in pre-market trading.
US women face shortages of estrogen patches, injectables, and vaginal creams due to surging demand. The FDA has been working with manufacturers to boost supplies since September. Companies like Viatris, Amneal, and Cost Plus Drugs report increased demand and production efforts. Shortages may be exacerbated by women switching from scarce patches to alternatives. Multiple manufacturers, including Hikma, American Regent, and Teva, are affected.
Amneal Pharmaceuticals, a US-based biopharmaceutical company, opened a new office in Ahmedabad, India, investing Rs 135 crore ($15 million). The 3.35 lakh sq ft facility will house 1,200 employees, supporting its global operations and recent acquisition of Kashiv BioSciences. The company also plans two new manufacturing facilities in Gujarat.
Viatris (VTRS), Amphastar (AMPH), ANI Pharmaceuticals (ANIP), and Amneal (AMRX) reported Q2 earnings. VTRS revenue grew 4.9% YoY, beating estimates. AMPH saw 5.4% growth, ANIP 25.9%, and AMRX 9.9%. Stocks reacted positively except ANIP, which fell 12%.
Genentech and Novartis sued Amneal Pharmaceuticals and its subsidiary Kashiv BioSciences for allegedly infringing nine patents related to the allergy drug Xolair. The lawsuit follows Amneal's FDA application for ADL-018, a biosimilar version of Xolair, which treats asthma and chronic rhinosinusitis.
Oppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
UBS reiterated a Buy rating on Amneal Pharmaceuticals (AMRX) with a $25.00 price target, citing growth in its hormone replacement therapy patch franchise. The stock is up 94% over the past year. Amneal reported Q2 earnings of $0.30 per share, beating estimates, and revenue of $796.2 million. Oppenheimer initiated coverage with an Outperform rating and $27.00 target, noting the impact of its Kashiv acquisition.
